Datma Introduces Federated Biomarker Explorer for Health Systems to Streamline Data Demand Insights
In an important move to enhance the integration of healthcare data and pharmaceutical needs, datma has unveiled its latest innovation — the Federated Biomarker Explorer for Health Systems. This tool is set to revolutionize how hospitals, cancer centers, and labs evaluate the demand for their health data prior to entering commitments or investing resources.
As healthcare systems frequently navigate the complexities of data-sharing partnerships, many are often faced with uncertainties around the utility of their data, especially in oncology research and precision medicine. Initial investments are made without clear forecasting of the potential returns, which can complicate decision-making processes.
According to Robin Edison, VP of Product at datma, “Health systems shouldn’t have to guess whether their data has immediate value to pharmaceutical companies. With this new tool, they can ascertain the demand for their data directly and determine when participation could bring immediate value.” This innovation complements the previously launched Federated Biomarker Explorer for Pharma, providing a comprehensive ecosystem that facilitates efficient communication between data custodians and pharmaceutical users.
Health systems interested in exploring how their data aligns with pharmacological needs can now register for early access to this groundbreaking tool. The Federated Biomarker Explorer allows institutions to provide high-level summaries of their available datasets, such as cancer types and biomarker findings — all without the need to share personal patient data, contractual obligations, or technological integrations at this initial stage.
The streamlined process allows health systems to receive alerts from datma when there's a match between their data offerings and pharmaceutical demand. This timely feedback loop ensures that health institutions can decide when and if to engage in business partnerships with greater clarity and confidence. By eliminating the element of uncertainty — a common pain point with many data-sharing agreements — the Federated Biomarker Explorer ensures that institutions can respond to real demands instead of speculative opportunities.
Noah Nasser, CEO of datma, described the transformative nature of this approach: “This model creates alignments before any commitment. Health systems can now engage with confidence, knowing there’s a real use case for their data that is being sought after.”
Furthermore, the new offering promotes bidirectional validation between both pharma and health systems. Pharmaceutical teams can utilize the tool to assess the feasibility and coverage of available real-world data, while also enabling health systems to gauge when their own data is pursued. This mutual validation minimizes risk and fosters confidence, allowing both parties to act decisively based on confirmed signals.
To recap, the Federated Biomarker Explorer for Health Systems is not just an innovation; it's a response to the demand for more transparent and efficient interactions within the healthcare data ecosystem. Interested parties can explore this opportunity further by registering for the early access program at www.datma.com/health-trial.
As datma continues to break down barriers to effective data utilization, this latest tool underscores the company's commitment to advancing precision medicine while safeguarding institutions' autonomy over their valuable data assets. For further information about datma and its innovative solutions, please visit their website.
As healthcare systems frequently navigate the complexities of data-sharing partnerships, many are often faced with uncertainties around the utility of their data, especially in oncology research and precision medicine. Initial investments are made without clear forecasting of the potential returns, which can complicate decision-making processes.
According to Robin Edison, VP of Product at datma, “Health systems shouldn’t have to guess whether their data has immediate value to pharmaceutical companies. With this new tool, they can ascertain the demand for their data directly and determine when participation could bring immediate value.” This innovation complements the previously launched Federated Biomarker Explorer for Pharma, providing a comprehensive ecosystem that facilitates efficient communication between data custodians and pharmaceutical users.
Health systems interested in exploring how their data aligns with pharmacological needs can now register for early access to this groundbreaking tool. The Federated Biomarker Explorer allows institutions to provide high-level summaries of their available datasets, such as cancer types and biomarker findings — all without the need to share personal patient data, contractual obligations, or technological integrations at this initial stage.
The streamlined process allows health systems to receive alerts from datma when there's a match between their data offerings and pharmaceutical demand. This timely feedback loop ensures that health institutions can decide when and if to engage in business partnerships with greater clarity and confidence. By eliminating the element of uncertainty — a common pain point with many data-sharing agreements — the Federated Biomarker Explorer ensures that institutions can respond to real demands instead of speculative opportunities.
Noah Nasser, CEO of datma, described the transformative nature of this approach: “This model creates alignments before any commitment. Health systems can now engage with confidence, knowing there’s a real use case for their data that is being sought after.”
Furthermore, the new offering promotes bidirectional validation between both pharma and health systems. Pharmaceutical teams can utilize the tool to assess the feasibility and coverage of available real-world data, while also enabling health systems to gauge when their own data is pursued. This mutual validation minimizes risk and fosters confidence, allowing both parties to act decisively based on confirmed signals.
To recap, the Federated Biomarker Explorer for Health Systems is not just an innovation; it's a response to the demand for more transparent and efficient interactions within the healthcare data ecosystem. Interested parties can explore this opportunity further by registering for the early access program at www.datma.com/health-trial.
As datma continues to break down barriers to effective data utilization, this latest tool underscores the company's commitment to advancing precision medicine while safeguarding institutions' autonomy over their valuable data assets. For further information about datma and its innovative solutions, please visit their website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.